Multilineage differentiation a b s t r a c t Background: The anterior-cruciate-ligament (ACL) contains mesenchymal stem cells (ACL-MSCs), suggesting the feasibility of regenerative treatments of this tissue. The immortalization of isolated cells results in cell-lines applicable to develop cell-based therapies.
demonstrated model systems can be used for further development of new cell-based regenerative approaches in anterior cruciate ligament research, which may lead to new therapeutic strategies in the future.
Injuries to the anterior cruciate ligament (ACL) result in a gross destabilization of the joint and the development of osteoarthritis. The functional restoration of the ligament is a key component in the prevention of secondary meniscal tears [1, 2] . The current standard of care is the surgical replacement of the torn ACL with an autologous semitendinosus or patellar tendon graft [3, 4] . However, high-level evidence suggests that the current standard of care is not resulting in substantially improved subjective outcomes [5, 6] . Further radiographic signs of osteoarthritis are observed in a high frequency after ACL injury and reconstruction [7] . In order to improve outcomes after ACL injury, novel regenerative therapies are being explored, that might allow restoring the proprioceptive nerve functions of the native ACL and omitting the harvest of an autologous tendon graft.
Multipotent mesenchymal stem cells (MSCs) might be used for the development of cell-based regenerative therapies. They can be isolated from a variety of different tissues including bone marrow, adipose tissue, trabecular bone, and tendon [8e11]. We have recently shown that cells isolated from torn ACLs of young donors possess a surface antigen expression profile highly similar to those of bone-marrowderived MSCs (BMSCs) and that they were able to undergo multilineage differentiation [12] , which qualifies them as MSC types [13] . Thus, the use of ACL-derived mesenchymal stem cells (ACL-MSCs) for regenerative therapies of the injured ACL appears attractive. However, ACL-MSCs can only proliferate in vitro for a limited number of times. By reducing the tendency to senescence using immortalization techniques, cell lines can be created. Those cell lines can improve the design and development of regenerative therapies by limiting the need of cell-isolations from donor tissues and reducing the variability introduced by different donors.
In this study, we have used human TERT gene transfer (encoding Telomerase reverse transcriptase) to immortalize ACL-MSCs derived from one young and one old donor. We hypothesized that the created cell lines (hTERT-ACL-MSCs) maintain the cellular morphology, surface antigen expression profile, and proliferative capacity of naive non-immortalized ACL-MSCs. Further we assessed, whether ACL-MSC cell lines maintain their capacity for multilineage differentiation.
Material and methods

Patient characteristics and tissue collection
ACL tissue was obtained from one young (17 years) and one old (73 years) ACL donor at the time of ACL reconstruction or joint replacement surgery, respectively; according to the protocol approved by our university's Ethics Committee and after informed consent of the patients and parents in case of minors.
Isolation and culture of ACL-MSCs
ACL-MSCs were isolated using collagenase digestion [12] . Tissue specimens were cut into smaller pieces followed by 12.5 U/ml collagenase NB4 (Serva Electrophoresis GmbH, Heidelberg, Germany) in complete medium consisting of Dulbecco's Modified Eagle Medium DMEM/Ham's F12 (PAA), 10% fetal bovine serum (FBS) (PAA Laboratories GmbH, Coelbe, Germany), 1% penicillin/streptomycin (PAA) and 50 mg/ml Lascorbic acid 2-phosphate (Sigma Aldrich GmbH, Taufkirchen, Germany) for 18 h. The released cells were separated from tissue debris using a cell strainer, pelleted at 1200 g for 5 min, resuspended in complete medium, and seeded in 75 cm 2 flasks. For all subsequent differentiation protocols, cells were cultivated in an incubator at 37 C and 5% CO 2 in a humidified atmosphere with media changes every 2e3 days. Cells were passaged using 1% trypsin (PAA) for 5 min for detachment, an equal volume of complete medium to stop the reaction, centrifugation at 1200 g for 5 min to pellet cells, and resuspension in complete medium, after which the cells were seeded at a minimal density of 5 Â 10 3 per ml in cell culture flasks.
Immortilization of ACL-MSCs
The viral overexpression of TERT (encoding human telomerase reverse transcriptase; hTERT) was used to immortalize third passage ACL-MSCs. The gene transfer was performed using a lentiviral vector, as previously described [14, 15] .
At a glance of commentary
Scientific background on the subject
The anterior cruciate ligament (ACL) contains mesenchymal stem cells. Immortalization of those cells results in cell-lines, which might be used for regenerative therapies in the future. The objective of this study was to characterize these ACL-derived cell-lines.
What this study adds to the field
The study demonstrates that cell-lines generated from ACL-derived stem cells maintain their morphology, surface antigen expression profile, and proliferative capacity while markers of senscence are reduced. The developed cell-lines maintained their multilineage differentiation capacity. The demonstrated model can be used for further development of new cell-based regenerative approches in ACL research. 
b-Galactosidase staining
Senescent cells were identified as previously described using the histological visualization of senescence-associated endogenous b-galactosidase activity [16, 17] . Briefly, following two washing steps with PBS (phosphate buffer solution), cells were fixed for 5 min in 2% (v/v) formaldehyde: 0.2% (v/v) glutaraldehyde (1:1). Following an additional PBS wash, cells were incubated with freshly prepared b-galactosidase staining solution at 37 C without extra addition of carbon dioxide for 16 h. Subsequently, the monolayer was washed twice with PBS for 5 min, rinsed with deionized water and analyzed microscopically.
Chondrogenic differentiation
Chondrogenic differentiation was performed in a pellet culture system, as previously described [18] . Third passage cells were detached from the plastic surface of culture flasks using trypsin digestion, counted and 2.5 Â 10 5 cells were transferred in 50 ml canonical tubes containing 500 ml of either chondrogenic or control media, followed by centrifugation at 1500 g.
Pellets were cultured in DMEM High Glucose medium supplemented with 1% penicillin/streptomycin, 40 ng/ml L-proline, 50 ng/ml L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate, 100 ng/ml pyruvate, 100 nM dexamethasone, 1% ITS (all Sigma-Aldrich, Schnelldorf, Germany), and human TGF-b1 (R&D Systems) for 28 days with the caps slightly opened to enable gas exchange. Control pellets were cultured in the absence of TGF-b1. RT-PCR of the chondrocyte marker genes ACAN (encoding aggrecan core protein), BGN (encoding biglycan), COMP (encoding cartilage oligomeric matrix protein) FMOD (encoding fibromodulin), as well as COL2A1 (encoding collagen alpha-1(II) chain) were used to gauge the degree of chondrogenic differentiation. COL10A1 (encoding collagen alpha-1(X) chain) expression was used to determine the degree of chondrocyte hypertrophy. Further qualitative histological assessment of alcian blue histology and type II collagen immunohistochemistry was performed.
Osteogenic differentiation
Osteogenic differentiation was performed in a monolayer culture system as previously described with slight modifications [18] . Cells were cultured in DMEM High Glucose medium containing 10% FBS, 1% penicillin/streptomycin, 10 ng/ml bone morphogenetic protein-2 (kindly provided by Prof. Dr. Walter Sebald, Emeritus Chair of Physiological Chemistry, Faculty of Medicine, University of Wuerzburg, Germany), 10 mM b-glycerophosphate, 50 ng/ml L-ascorbic acid 2phosphate sesquimagnesium salt hydrate, and 100 nM dexamethasone (all Sigma Aldrich GmbH) for 28 days. Control cells were cultured in DMEM High Glucose containing 10% FBS and 1% penicillin/streptomycin only. RT-PCR of the osteocytespecific marker gene ALPL (encoding alkaline phosphatase, tissue-nonspecific isozyme) and the qualitative assessment of alkaline phosphatase and alizarin red positive areas were performed to gauge the degree of osteogenic differentiation.
Adipogenic differentiation
Adipogenic differentiation was performed in a monolayer culture system according to a modified protocol described before [18] . Cells were incubated with DMEM High Glucose containing 10% FBS, 1% penicillin/streptomycin, 1 mg/ml insulin, 100 mM indomethacin, 0.5 mM 3-isobutyl-1- 
RNA isolation and RT-PCR
RNA was isolated using the NucleoSpin© RNA II kit (Machery-Nagel GmbH, Dueren, Germany) according to the manufacturer's instructions. The pellets of chondrogenic cultures were previously homogenized in the first buffer of the respective kit using a pestle. 1 mg of isolated RNA was transcribed into cDNA using the BioScript™ kit (Bioline GmbH, Luckenwalde, Germany) with random hexamer primers (Life Technologies GmbH, Darmstadt, Germany) according to the manufacturer's protocols. Gene expression was analyzed using RT-PCR with reaction mixtures containing 3 ml 10x reaction buffer (shipped with the MangoTaq™ from Bioline), 1 ml 10 mM dNTP mixture (Bioline), 1 ml of each forward and reverse primer corresponding to a concentration of 5 mM (See Table 1 for primers) and 3 ml MangoTaq™ polymerase (5000 U/ml, Bioline) and 1 ml of cDNA in 21.9 ml distilled water. The PCR was started by an initial denaturation step at 94 C for 3 min followed by cycles of denaturation at 94 C for 45 s, primer annealing for 45 s with primer specific temperatures illustrated in Table 1 , and an elongation step at 72 C for 1 min. Subsequent agarose gel electrophoresis was performed using 1.5% agarose gels (Merck) containing 0.5 mg/l ethidium bromide (AppliChem GmbH, Darmstadt, Germany) and 0.5x TBE buffer at 0.9 V/cm of gel length. Gels were documented photographically using the Bio Profile software (LTF, Wasserburg, Germany) and analyzed densitometrically using the GelAnalyzer software (http://www.gelanalyzer.com). For all targeted gene expression analyses EEF1A1 (encoding Elongation factor 1-alpha) was used as housekeeping gene.
Results
Cellular morphology and surface antigen expression
In monolayer culture, eighth passage hTERT-ACL-MSCs possessed a spindle-shaped morphology similar to non-passaged ACL-MSCs [ Fig. 1] . A strong expression of the surface markers CD44, CD90, CD105, and STRO-1 was observed in hTERT-ACL-MSCs [ Fig. 2 ].
Proliferative capacity and cellular senescence
The short-term ATP activity assessed at day 2, 4, betaegalactosidase activity, indicating cellular senescence. In comparison, the staining intensity in hTERT-ACL-MSCs was reduced [ Fig. 4 ].
Chondrogenic differentiation
Cultivation of hTERT-ACL-MSCs as pellets in chondrogenic medium resulted in an upregulation of the proteoglycan encoding ACAN, BGN, and COMP, when compared to noninduced hTERT-ACL-MSC pellets. Fig. 5 shows the chondrogenic differentiation of the immortalized ACL fibroblasts. Chondrogenic differentiation was evaluated using alcian blue staining to visualize proteoglycans (A), hematoxylin and eosin staining to illustrate the cell nuclei (B), immunohistochemistry for the detection of COL2 (C) and by RT-PCR investigating chondrocyte-specific marker genes (D). hTERT ACL young fibroblasts are denoted as young and hTERT ACL old fibroblasts as old. Notably, FMOD expression was only induced in the cell line generated from the young donor [ Fig. 5D ]. Concomitantly, the alcian blue staining intensity was slightly increased in hTERT-ACL-MSCs after chondrogenic induction [ Fig. 5A ]. The type II collagen encoding COL2A1 was only slightly unregulated in hTERT-ACL-MSCs on the mRNA level, while a strong increase in type II collagen was detected on the protein level in the cell line generated from the young donor only. The COL10A1 expression was upregulated in hTERT-ACL-MSCs from both donors.
Osteogenic differentiation
Cultivation of hTERT-ACL-MSCs as monolayer in osteogenic medium resulted in an upregulation of ALPL gene expression [ Fig. 6C ], as well as a strong increase in staining for alkaline phosphatase activity [ Fig. 6A ]. Only a slight increase in alizarin red staining was observed at the assessed time point after induction in hTERT-ACL-MSCs [ Fig. 6B ].
Adipogenic differentiation
Cultivation of hTERT-ACL-MSCs as monolayer in adipogenic medium resulted in strong upregulation of LPL and a slight upregulation of PPARG gene expression [ Fig. 7B ]. Concomitantly sporadic lipid vacuoles were observed in the induced hTERT-ACL-MSCs [ Fig. 7A ].
Discussion
The purpose of this study was to assess, whether cell lines that were generated from isolated ACL-MSCs using TERT gene transfer maintain the cellular morphology, surface antigen expression profile, and proliferative capacity of naive nonimmortalized ACL-MSCs. Using two cell lines, one generated from a young donor (17 years) and one from an old donor (73 years), we did not observe morphological differences between the immortalized cell lines and the non-immortalized ACL-MSCs. The cell-lines maintained a strong expression of CD44, CD90, CD105, and STRO-1 surface markers, which are expressed on human MSCs, suggesting that the immortalized cell lines maintain their potential for multilineage differentiation as confirmed subsequently. No difference was observed in regards to the short-term proliferative capacity (the proliferative capacity within one passage) between the cell lines and the non-immortalized ACL-MSCs. After long-term culture the immortalized cell lines demonstrated a reduced betaegalactosidase activity, indicating reduced senescence in the cell lines, when compared to the non-immortalized ACL-MSCs. Further, we have assessed whether the immortalized cell lines maintain their capacity for multilineage differentiation. Therefore, the two cell lines were cultured in chondrogenic, osteogenic, adipogenic media, or control media that were lacking the key differentiation factors. The immortalized cell lines maintained capable to differentiate along the chondrogenic, osteogenic, and adipogenic lineages. Specifically, the successful chondrogenic differentiation was demonstrated by increased glycosaminoglycan expression (increased alcian blue staining and ACAN, BGN, and COMP expression). Notably, an increased type II collagen expression on the protein level was only observed in the cell line generated from the young donor. Although not being the objective of this study, the finding might suggest age-specific differences in the capacity for chondrogenic differentiation. However, no statistical testing could be performed, since this study included one cell line per age group. The evaluation of this phenomenon requires future, adequately powered studies. The successful differentiation of the immortalized cell lines along the osteogenic and the adipogenic lineages were indicated by the increased alkaline phosphatase activity and in ALP expression, and the increased presence of oil red O stained lipid vacuoles and increased LPL and PPARG expression, respectively.
This study is the proof of concept that ACL-derived MSCs can be subjected to an immortalization procedure, specifically the lentiviral transfer of human TERT, to create a cell line that maintains the characteristics of the non-immortalized ACL-MSCs. Such model-systems can facilitate the development of new cell-based regenerative approaches, since they eliminate the need for frequent isolations of ACL-MSCs. Further, they eliminate intra-individual variations in the characteristics of the utilized mesenchymal stem cells throughout experiments and thus might reduce the number of needed biological replicates.
Although this experiment demonstrates that the creation of cell-lines from ACL-MSCs is feasible, it was not designed to test for subtle differences in the characteristics of immortalized cell lines and non-immortalized ACL-MSCs. However, towards the clinical application of cell-therapies that are based on ACL-MSCs, autologous non-immortalized ACL-MSCs would be used. Immortalized cell-lines are a tool to enhance the evaluation of the cell-characteristics and the development of new therapies.
